Phase 1 Trial of New Therapy Begins for Interstitial Lung Diseases Such as Sarcoidosis
aTyr Pharma has dosed the first person in its Phase 1 study of iMod.Fc (ATYR1923) — an investigational therapy developed for patients with interstitial lung diseases, including sarcoidosis. The study is the first to test the compound in humans and will compare the treatment to a placebo in healthy…